Related by context. All words. (Click for frequent words.) 54 observational cohort study 52 retrospective cohort 51 retrospective cohort study 49 prospective nonrandomized 47 Normative Aging Study 47 prospective longitudinal 47 retrospective observational study 47 longitudinal cohort study 47 transrectal ultrasound guided 47 longitudinal observational study 46 multicentre prospective 46 COPD exacerbation 46 Acute Decompensated Heart Failure 46 Framingham Offspring 46 patientswith 46 retrospectively analyzed 46 prospective randomized multicenter 46 meta regression 45 Framingham Offspring Study 45 rheumatoid arthritis crohn disease 45 nondemented 45 histologically proven 44 bacterial prostatitis 44 familial aggregation 44 prospectively enrolled 44 underwent CABG 44 metaanalysis 44 atherothrombotic disease 44 ILLUSTRATE 44 Carotid Revascularization Endarterectomy vs. 44 FDG PET scans 44 RE LY trial 44 conducted retrospective cohort 44 Comma separation 44 treatment naive genotype 44 IPAH 44 prognostic variables 44 periprocedural MI 44 Multi Ethnic Study 44 visceral metastases 43 null responder HCV 43 substudy 43 lacunar 43 Identification ALI 43 prostate cancer CaP 43 Intervention Trial 43 hemodialysis patients 43 NATRECOR ® 43 Randomized Evaluation 43 clinico pathological 43 spirometric 43 prospectively randomized 43 randomized controlled trials RCTs 43 tumor histology 43 nucleoside naive 43 prospective multicentre 43 ANCOVA 43 angiographically 43 BARI 2D 43 MADIT 42 retrospective observational 42 HSCT 42 logistic regression analyzes 42 metastatic malignant melanoma 42 multicenter randomized clinical 42 Baltimore Longitudinal Study 42 prospective observational cohort 42 conditional logistic regression 42 Multicenter 42 Multiethnic Cohort Study 42 prospective multicenter 42 underwent radical prostatectomy 42 MEND CABG 42 immunocompetent 42 OLYMPIA registry 42 VADT 42 LHRH receptor positive 42 prostate cancer PCa 42 ELBW infants 42 nulliparous women 42 subclinical atherosclerosis 41 histologically confirmed 41 VITAL Trial 41 prospective observational 41 multivariable analysis 41 gadolinium enhanced 41 Prostate Lung Colorectal 41 cohort 41 randomized multicenter trial 41 Edge STudy 41 psychiatric outpatients 41 thyroidectomy 41 retrospectively reviewed 41 underwent resection 41 bivariate analyzes 41 prospective cohort 41 GH deficiency 41 ug dose 41 numerical identifier 41 HCV SPRINT 41 NIH CPSI 41 melanocytic nevi 41 undergoing coronary angiography 41 observational cohort 41 METHODS 41 CORE OM 41 pretransplant 41 Wisconsin Sleep Cohort 41 arteriography 41 multiple logistic regression 41 T2 lesions 41 hemodynamically significant 41 Atherosclerosis MESA 41 AIR2 Trial 41 Randomized controlled 41 syndromal 41 ROCKET AF 41 T2DM 41 logistic regression analysis 41 liver transplant recipients 41 abnormal cytology 40 ConclusionThis 40 multicenter Phase II 40 undergone radical prostatectomy 40 multicentre randomized 40 sociodemographic characteristics 40 atrioventricular block 40 PARTNER Trial 40 FAME Study 40 AIR CF1 40 prostate carcinoma 40 postdischarge 40 Swedish Mammography Cohort 40 efficacy evaluable 40 psychiatric comorbidities 40 Univariate analysis 40 relapsed MM 40 double blinded randomized 40 placebo controlled dose escalation 40 logistic regression model 40 SYNTAX trial 40 DAPT 40 blinded randomized placebo controlled 40 epithelial ovarian cancer 40 null responder 40 Index CDAI 40 rFSH 40 carotid stenosis 40 efavirenz EFV 40 NSTEMI 40 undergoing radical prostatectomy 40 Millennium Cohort Study 40 MEND CABG II 40 AIR CF3 40 SYNTAX 40 multivariate logistic regression 40 PLCO 40 phase IIIb 40 NHANES surveys 40 dosing cohorts 40 HIV seronegative 40 posttransplant 40 VLBW infants 40 HIV HCV coinfected 40 advanced neoplasia 39 BMI z 39 Netherlands Cohort Study 39 multicenter randomized placebo controlled 39 trials RCTs 39 Screening Trial 39 HORIZONS AMI trial 39 MADIT II 39 HIV seroconversion 39 acute leukemias 39 T1c 39 multivariate analyzes 39 chest radiographs 39 euthyroid 39 multicenter study 39 CALGB 39 postoperative complication 39 ECG abnormalities 39 undergoing CABG 39 dietary questionnaires 39 Phase IIIb 39 CTEPH 39 lymphoproliferative disorder 39 nonvertebral fractures 39 hematopoietic cancers 39 Polyp Prevention Trial 39 TG MV 39 elevated troponin 39 ischemic cardiomyopathy 39 colorectal adenoma 39 CARDIA study 39 CHAMPION PCI 39 plasma pharmacokinetics 39 carotid plaques 39 Phase IIIb study 39 multicenter randomized controlled 39 randomized multicenter 39 multicenter prospective 39 risperidone olanzapine 39 DMIST 39 EINSTEIN DVT 39 Elastic IP 39 HF ACTION 39 controlled multicenter 39 randomization 39 CASS Certified 38 Babe Waxpak Box 38 subset 38 QuickAddress Pro 38 pheochromocytoma 38 microbiologically evaluable 38 psychiatric comorbidity 38 multicentre 38 paroxysmal AF 38 RE LY 38 www.adt.com 38 PFO migraine 38 cryptogenic stroke 38 developmental dysplasia 38 EVEREST II 38 randomisation 38 PREVENT IV 38 SORT OUT III 38 demographic psychographic 38 randomized crossover 38 onset diabetes mellitus 38 STEP BD 38 myocardial infarctions MI 38 certolizumab 38 ragweed allergic 38 EchoCRT 38 TMC# C# 38 geodemographic 38 Study ARIC 38 univariate analyzes 38 distal radial fractures 38 cryptographic hash 38 peptic ulcer bleeding 38 preserved LVEF 38 ACCOMPLISH 38 virologic response EVR 38 proband 38 sociodemographic factors 38 multivariate Cox 38 multicentre study 38 BR.# 38 clinicopathological 38 multivariable logistic regression 38 lowest tertile 38 Acetonide 38 renal tumors 38 singleton pregnancies 38 Health Initiative Observational 38 zip disks 38 underwent bariatric surgery 38 randomized blinded 38 Thrombolysis 38 TAXUS VI 38 multicenter trials 38 CAMMS# 38 ABSSSI 38 http:/www.thehartford.com 38 posttreatment 38 T1DM 38 radical nephrectomy 38 RE LY ® 38 MADRS score 38 pharmacodynamic effects 38 REVIVE Diabetes 38 Chima expulsion 38 ADHF 38 cognitively normal 38 Multicenter AIDS 37 perioperative complications 37 Kruskal Wallis test 37 seroconverted 37 de novo AML 37 postintervention 37 HIV uninfected 37 MVax R 37 underwent liver transplantation 37 ipsilateral stroke 37 chronic periodontitis 37 confidence interval #.#-#.# 37 WiseAnalytics Lyndsay Wise 37 preoperative PSA 37 NMIBC 37 TEAEs 37 tpratt@cdispatch.com 37 clinically localized prostate 37 Kaplan Meier curve 37 patients undergoing CABG 37 comorbidity 37 ENGAGE AF TIMI 37 serum PTH 37 Osteoporotic Fractures 37 Clinical Antipsychotic Trials 37 hepatectomy 37 Joab e mail 37 recurrent endometrial cancer 37 nulliparous 37 subanalysis 37 femoral neck fracture 37 CATIE AD 37 subnetting 37 http:/www.thehartford.com/ 37 hepatic resection 37 HBeAg negative 37 antiretroviral naïve 37 germline mutations 37 Atherosclerosis Risk 37 serum lipid levels 37 symptomatic BPH 37 secondary efficacy endpoint 37 Ovarian PLCO Cancer 37 nephron sparing surgery 37 suicide attempters 37 bvito@dentonrc.com 37 subtrochanteric 37 ELBW 37 Randomized trials 37 TAXUS Express Stent 37 RTOG 37 Subgroup analysis 37 limiting generalizability 37 meta analysis 37 knee arthroplasty 37 longitudinal study 37 Prostate Cancer Prevention 37 KRAS mutations occur 37 evaluable subjects 37 CCR5 tropic HIV 37 fragility fractures 37 multicenter randomized double 37 Phase Ib clinical 37 VLAN tags 37 http:/www.tektronix.com 37 postmenopausal women 37 randomized multicentre 37 NSABP B 37 prospective multicenter randomized 37 randomizing patients 37 antiretroviral naive 37 PCa 37 ascending dose 37 nonrandomized 37 clinicopathological features 37 psychiatric morbidity 36 placebo controlled clinical 36 EMPHASIS HF 36 AC servos 36 Feasibility Trial 36 coronary angiograms 36 automatically categorizes 36 www.cypresscom.net 36 dose escalation phase 36 Collaborative Perinatal Project 36 serum GGT 36 XIENCE V PROMUS Stent 36 Joab Jackson@idg.com 36 androgen deprivation 36 HCV infected 36 randomized Phase IIb 36 prospective randomized placebo 36 http:/www.level3.com/ 36 SCr 36 multicenter phase 36 www.coopervision.com 36 Logistic regression 36 DavidJSanders@aol.com 36 kgray@unionleader.com 36 Sprague Dawley rats 36 RBC folate 36 ± SD 36 chest radiograph 36 opioid dependent 36 symptomatic VTE 36 multicentre randomized double 36 Zip +4 36 perioperatively 36 Phase III randomized controlled 36 www.axcelis.com 36 sociodemographic 36 PSA nadir 36 used fek9wnr 36 breast carcinoma 36 SWOG 36 Exclusion criteria 36 seropositivity 36 operable pancreatic cancer 36 inhaled corticosteroid therapy 36 nonpsychotic 36 nonadherent 36 Sarano 36 WHEL 36 RRMS patients 36 cbreeding@dentonrc.com 36 Birth Cohort 36 covariate 36 Multicenter Automatic Defibrillator Implantation 36 multivariable Cox 36 relapsed AML 36 unique identifier 36 mg BID dose 36 genotypic resistance 36 prospective randomized controlled 36 liver histology 36 HNSCC 36 carotid artery narrowing 36 paclitaxel eluting stents 36 CC genotype 36 mCRPC 36 CARDIA 36 subgroup analyzes 36 ACR Pedi 36 NetID 36 nonmetastatic prostate cancer 36 placebo controlled Phase III 36 osteopenic 36 nomogram 36 LV dysfunction 36 genomewide association studies 36 telomere lengths 36 Number SSN 36 links summarizes personalizes 36 mdavis@wbap.com 36 % CI #.#-#.# [008] 36 john ribeiro@idg.com 36 operable breast cancer 36 aboedeker@dentonrc.com 36 cirrhotic patients 36 TKAs 36 TT genotype 36 recurrent glioblastoma multiforme 36 euthymic patients 36 pharmacokinetic PK 36 extensive metabolizers 36 undetectable HBV DNA 36 Multivariate analyzes 36 glycated hemoglobin levels 36 addresses 36 randomized 36 cystectomy 36 ascending dose study 35 % CI #.#-#.# [007] 35 nrp@citistates.com 35 serum estradiol 35 morphometric vertebral fractures 35 Randomised 35 SIMPADICO 35 comorbidities 35 ALLEGRO 35 TAXUS IV 35 androgen suppression 35 onset atrial fibrillation 35 BMI percentile 35 postoperative mortality 35 EURIDIS 35 Yan Balayan registered 35 oral prednisolone 35 recurrent venous thromboembolism 35 mg/m2 dose 35 ENDEAVOR clinical 35 randomized controlled clinical 35 APTIVUS r 35 blind placebo 35 homocysteine concentrations 35 composite endpoint 35 Twin Registry 35 geocodes 35 MetS 35 everolimus eluting stents 35 COU AA 35 stage IIIB 35 phase IIb study 35 timepoints 35 TAXUS V 35 conjugated equine estrogen 35 aged ≥ 35 radical prostatectomy RP 35 REYATAZ r arm 35 ABSORB trial 35 recurrent GBM 35 nonfatal MI 35 dosing cohort 35 cirrhotic 35 graft dysfunction 35 nondiabetic patients 35 nonoperative treatment 35 clinically meaningful improvement 35 previously untreated follicular 35 intravascular ultrasonography 35 HeFT 35 holly.huffman @ theeagle.com 35 lymphadenectomy 35 neurodevelopmental impairment 35 SUID 35 longitudinal studies 35 mildly symptomatic 35 hepatitis C genotype 35 affective disorder 35 MIST II 35 Anti Spam Gateway 35 geolocate 35 sociodemographic variables 35 dosage regimens 35 www.bv.com 35 SSL HTTPS 35 NSTE ACS 35 cells mcL 35 chronicity 35 Cohorts 35 syates@capitalpress.com 35 histologies 35 HCV genotype 1 35 prospectively defined 35 URL Uniform 35 smartcard authentication 35 HPTN 35 MADIT CRT 35 odds ratios ORs 35 GAC NASDAQ GEAC 35 http:/www.tektronix.com/ 35 Alzheimer Disease Neuroimaging Initiative 35 #.#.#.# [044] 35 NIHSS score 35 timepoint 35 iclark@unionleader.com 35 randomized controlled trial 35 gkeizer@computerworld.com 35 total hip arthroplasty 35 HGPIN 35 kidney allograft 35 double blinded placebo 35 baseline LDH 35 pmccoy@capitalpress.com 35 IDH1 mutation 35 onset AF 35 multicenter randomized 35 mcg linaclotide 35 receiving highly emetogenic 35 response pCR 35 Kaplan Meier analysis 35 AIM HIGH 35 dyslipidaemia 35 XIENCE V demonstrated 35 myocardial infarction MI 35 intravenous diuretics 35 Registered unitholders 35 femoral neck BMD 35 logistic regression models 34 subclinical hypothyroidism 34 adiponectin concentrations 34 hking@arkansasnews.com 34 undergoing bariatric surgery 34 acid suppressive medications 34 % CI #.#-#.# [003] 34 lipid lowering medications 34 www.Level3.com 34 automatically uploads 34 pegylated interferon alfa 2b 34 efficacy endpoint 34 Ovarian Cancer Screening 34 affective psychosis 34 ip addresses 34 User Name 34 habitual snoring 34 lmbrown@dentonrc.com 34 confounding variables 34 MIRP 34 warfarin therapy 34 roby@talkbusiness.net 34 vertebral fracture 34 confounder 34 atheroma volume 34 BRCA2 mutation carriers 34 Phase Ib IIa clinical 34 NHANES III 34 thrombolytic therapy 34 Primary endpoints 34 URTI 34 observational study 34 thromboembolic complications 34 dfielder@dentonrc.com 34 multicenter 34 blinded placebo controlled 34 blewis@dentonrc.com 34 fragility fracture 34 systolic dysfunction 34 MERLIN TIMI 34 melphalan prednisone 34 virological response 34 APEX AMI trial 34 interquartile range 34 Wistar rats 34 hip BMD 34 pCR 34 #.#.#.# [002] 34 biochemical recurrence 34 calthomas@tribune.com 34 acetabular fracture 34 randomized multicenter Phase III 34 asymptomatic metastatic 34 PCPT 34 inhaled tobramycin 34 debulking surgery 34 www.zumiez.com 34 inactive textual references 34 placebo controlled trials 34 lvarner@seattletimes.com 34 blind randomized controlled 34 GH deficient 34 MCPmag.com editors 34 CHAMPION PLATFORM 34 MMSE score 34 colorectal neoplasia 34 SCD HeFT 34 CI #.#-#.# [001] 34 BMD measurements 34 CR nPR 34 www.talkbusiness.net 34 definite stent thrombosis 34 identifi cation 34 http:/www.Level3.com 34 Communities ARIC study 34 jvijayan@computerworld.com 34 dysglycemia 34 study 34 coronary revascularization 34 prospectively evaluated 34 Barracuda Spam Firewalls 34 estimated glomerular filtration 34 p = #.# [003] 34 macroalbuminuria 34 neoadjuvant 34 www.headwaters.com 34 RESIST studies 34 hsCRP levels 34 extracapsular extension 34 esophagectomy 34 Certiport prepares 34 seronegative 34 biochemical relapse 34 dose regimens 34 nancykruh@swbell.net 34 prespecified 34 wmckenzie@dallasnews.com 34 Undeliverable 34 seminal vesicle invasion 33 myocardial infarctions 33 Phase III randomized 33 QTc 33 HBeAg negative chronic hepatitis 33 postmenopausal 33 tertiles 33 mcg BID 33 virologic response 33 SNP rs# [002] 33 endoscopic remission 33 jbalter@seattletimes.com 33 Kaplan Meier method 33 phase IIa clinical 33 dose escalation Phase 33 jbrummett@arkansasnews.com 33 indentifies 33 MADIT CRT trial 33 www.hearstargyle.com 33 advanced adenoma 33 cleubsdorf@dallasnews.com 33 univariate 33 liver biopsies 33 prospective randomized 33 non squamous histology 33 phase Ib 33 Subgroup analyzes 33 covariates 33 NHANES 33 CDYNE 33 n = 33 achieved sustained virological 33 GIK infusion 33 #.#.#.# [045] 33 ellengoodman@globe.com 33 serum IGF 33 Kaplan Meier curves 33 virologic 33 HCV genotype 33 sustained virological response 33 allele frequencies 33 univariate analysis 33 pheinkel-wolfe@dentonrc.com 33 multicenter clinical 33 HBeAg positive 33 pharmacokinetics PK 33 confidence interval CI 33 UKPDS 33 ccarlisle@dentonrc.com 33 multicast routing 33 userID 33 btabor@dentonrc.com 33 robert mcmillan@idg.com 33 imatinib therapy 33 sirolimus eluting stents 33 Young Adults CARDIA 33 http:/www.comedycentral.com/ 33 sd = 33 digit zip code 33 elevated LDL cholesterol 33 HTTPS Hypertext Transfer 33 Stage IIIb 33 incomplete revascularization 33 mlies@capitalpress.com 33 jrutter@lnpnews.com 33 Nutrition EPIC 33 kgardner@thetranscript.com telephone extension 33 hanshew@herald-dispatch.com 33 malkinblog@gmail.com 33 suboptimal adherence 33 april.avison @ theeagle.com 33 Phase 1b clinical 33 elevated CRP 33 completely resected 33 BRCA mutation carriers 33 Cohort Study MACS 33 hippocampal volumes 33 HTTP HTML 33 godsquad@telecaretv.org 33 PreCISe study 33 viral kinetic 33 preoperative chemotherapy 33 pthibodeau@computerworld.com 33 Randomized 33 blind placebo controlled 33 pharmacodynamics PD 33 passwords PINs 33 adjuvant tamoxifen 33 GISSI HF 33 bramsey@seattletimes.com 33 T2D 33 dyads 33 ovariectomized 33 National Birth Cohort 33 radical cystectomy 33 DLTs 33 p = .# [002] 33 lipid lowering therapy 33 randomized placebo controlled 33 LVSD 33 weekly subcutaneous injections 33 nonfatal myocardial infarction 33 tipranavir r 33 Phase 1b trial 33 digit alphanumeric 33 unipolar depression 33 Baseline characteristics 33 nondepressed 33 Longitudinal Study 33 www.guycarp.com 33 parous 33 placebo controlled Phase 33 #.#.#.# [025] 33 zip +4 33 mITT population 33 RSD# oral 32 Cohort 32 elective percutaneous coronary 32 histologically 32 hashed passwords 32 Mania Rating Scale 32 jhmi.edu 32 teepencolumn@earthlink.net 32 elotuzumab 32 stage IIIb 32 geo coding 32 http:/www.aa.com/ 32 subgroup 32 ERSPC 32 bbragg@adn.com 32 ≥ 32 recurrent VTE 32 lymphocyte count 32 blinded randomized controlled 32 solifenacin 32 locoregional 32 jim@cyberdads.com 32 Cohort Study 32 randomized controlled trials 32 txt file 32 Operative mortality 32 www.amedisys.com 32 DAS# scores 32 ellengoodman1@me.com 32 events SAEs 32 IL#B 32 dose escalation clinical 32 Kay Tee Khaw 32 mg kg cohorts 32 Coronary Artery Risk 32 Echoworx Secure Mail 32 ECASS 32 eplerenone 32 www.gardencityny.net 32 ECOG PS 32 kidney transplant recipients 32 identifiers 32 Threaded SMS 32 PAYPAL shipped 32 SSL authentication 32 MSAG 32 www.maxlinear.com 32 randomized clinical 32 heavily pretreated 32 dose dose escalation 32 hydroxyvitamin D levels 32 estimated GFR 32 RCTs 32 bkrauter@capitalpress.com 32 VTE 32 doxorubicin docetaxel 32 Complications Trial DCCT 32 locoregional recurrence 32 randomized double 32 nonexposed 32 placebo controlled 32 cabarrus@charlotteobserver.com 32 EMPHASIS HF trial 32 serum samples 32 knee OA 32 subkeys 32 pooled comparator 32 squamous histology 32 Malformed 32 landmark ATHENA 32 normotensive 32 CAN SPAM compliance 32 adenoma recurrence 32 coinfected patients 32 bivariate 32 www.comedycentral.com 32 pmcilheran@journalsentinel.com 32 Latino surnames 32 ADHD RS 32 tertile 32 rdreher@dallasnews.com 32 nhunter@jacksonsun.com 32 ST elevation myocardial 32 SCIg 32 castration resistant prostate cancer 32 prospectively 32 GYTS 32 geocoded 32 nonobese 32 refractory CLL 32 WEP keys 32 pager PDA 32 insulin detemir 32 authors conclude 32 follicular NHL 32 NET Passport 32 Partial Responses 32 instant messaging video conferencing 32 subpopulation 32 noninferiority 32 Appending 32 NET Remoting 32 HbA1c levels 32 RECIST criteria 32 remission CR 32 multicenter placebo controlled 32 CYPHER Stent 32 specific antigen PSA 32 section I.1 32 subgroups 32 www.tektronix.com 32 Birth certificate 32 rheumatoid arthritis viral infections 32 ALLHAT 32 Phase IIIb clinical 32 Flu Cy 32 davidignatius@washpost.com 32 spoofing phishing 31 #.#.#.# [022] 31 PSADT 31 dose escalation 31 MD5 hash 31 addresses birthdates 31 response.enbridgeus.com 31 suntrust.com 31 genotyped 31 Address Validation 31 quick registraton 31 NCOALink 31 baseline CD4 31 evaluable 31 completers 31 premenopausal 31 GeoCast Web 31 bklucas#@aol.com 31 highest tertile 31 stage IIIb IV 31 paclitaxel carboplatin 31 alphanumeric code 31 Avon Longitudinal Study 31 verification PIV 31 IV NSCLC 31 identifies 31 genotype 1a 31 schizotypal traits 31 BMI ≥ 31 CaP 31 eGFR 31 beta blocker therapy 31 plasma folate 31 acute myelogenous leukemia AML 31 advanced adenomas 31 HYVET 31 randomized trials 31 NYSE AMEX TCX 31 phase IIa 31 symmetric encryption 31 randomized Phase III 31 AirPort Extreme Update #-# 31 minister Giorgios Papakonstantinou 31 relapsed GBM 31 numeric identifiers 31 dual stack IPv#/IPv# 31 www.pioneerelectronics.com 31 probands 31 logons 31 Sandra Boodman 31 dose escalation study 31 domain spoofing 31 % CI #.#-#.# [006] 31 PRECiSE 31 mcg doses 31 recursive DNS 31 ldickie@seattletimes.com 31 http:/www.aa.com 31 www.socialsecurity.gov onlineservices 31 ELCAP 31 potent antiretroviral therapy 31 #mg QD [002] 31 treasures@knology.net 31 baseline HbA1c 31 UDP packet 31 fonts font 31 Append 31 CVD mortality 31 CIN3 31 immunosuppressive regimen 31 mail@democracynow.org 31 DSL NET1 #-#-#-# 31 @ tidewaternews.com 31 SAML token 31 blind multicenter 31 ZIP +4 31 nonfasting triglyceride levels 31 rharkn@aol.com 31 CLBP 31 randomized #:#:# 31 #.#.#.# [009] 31 treatment naļve 31 microalbuminuria 31 gbass@coxnews.com 31 statistically nonsignificant 31 DCCT 31 cART 31 chemoradiotherapy 31 periprocedural 31 subsample 31 dwilkins@capitalpress.com 31 ritonavir boosted 31 #.#.#.# [039] 31 placebo controlled studies 31 Invalid E 31 % CI #.#-#.# [004] 31 HTTP SMTP 31 median CD4 30 controlled dose escalation 30 HbA1C levels 30 plasma uric acid 30 label dose escalation 30 Phase IIa trial 30 nondiabetic 30 eculhane@postcrescent.com 30 http:/www.comedycentral.com 30 prevalences 30 postchat@aol.com 30 P = .# 30 lymphocytosis 30 identifier 30 mhamblen@computerworld.com 30 neoadjuvant chemotherapy 30 AVADO 30 attain statistical significance